New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
08:36 EDTNUVANuVasive announces favorable resolution of patent lawsuit against Cadwell Labs
NuVasive announced that it reached a settlement agreement with Cadwell Laboratories in a lawsuit involving NuVasive's patented neuromonitoring technology. NuVasive filed the lawsuit in December 2012 asserting that Cadwell infringed on the company's patented neuromonitoring technology, including the integration of nerve monitoring technology during lateral approach spine surgery. As part of the settlement reached between the parties, Cadwell has agreed to exit the lateral spine surgery market, and to no longer provide products, services, or support for lateral approach spine fusion surgeries. In addition, certain of Cadwell's future products may be required to openly attribute intellectual property ownership to NuVasive and may require a 5% fee paid to NuVasive.
News For NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
07:37 EDTNUVAJPMorgan to hold a conference
Subscribe for More Information
January 13, 2015
10:00 EDTNUVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:12 EDTNUVANuVasive downgraded to Neutral from Buy at Summer Street
Subscribe for More Information
07:28 EDTNUVANuVasive price target raised to $55 from $50 at RW Baird
Subscribe for More Information
January 12, 2015
16:06 EDTNUVANuVasive COO Valentine to step down, Miles named as successor
NuVasive announced changes to its leadership team designed to enhance the company's organizational alignment. Pat Miles, NuVasive's current President of Global Products and Services, will assume an expanded role as President and Chief Operating Officer. The company also announced that NuVasive's COO Keith Valentine will step down from that role and be leaving the company effective April 30. Valentine is committed to working with the company to ensure a seamless transition of responsibilities over the coming months, the company said.
16:04 EDTNUVANuVasive sees Q4 revenue $203M, consensus $199.95M
Subscribe for More Information
16:04 EDTNUVANuVasive sees FY15 revenue $810M, consensus $811.7M
Subscribe for More Information
16:02 EDTNUVANuVasive sees FY14 revenue $761M, consensus $758.16M
NuVasive provided a business and financial performance update, including the announcement of select preliminary unaudited financial results for FY14. The company sees preliminary FY14 revenue of approximately $761M, which reflects 11% growth over the prior year or 12% on a constant currency basis. Preliminary FY14 non-GAAP operating margin is anticipated to exceed guidance of 16.5%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use